Questcor Pharmaceuticals Inc

Questcor Pharmaceuticals — JP Morgan Healthcare Conference 2012

30 slides from Questcor Pharmaceuticals's conference presentation, Jan 9, 2012

  1. Slide 1: January 2012 JP Morgan Healthcare Conference

    January 2012 JP Morgan Healthcare Conference Exhibit 99.2 January 2012 JP Morgan Healthcare Conference

  2. Slide 2: Safe Harbor Statement

    2 Safe Harbor Statement Except for the historical information contained herein, this presentation contains forward-looking statements that are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to

  3. Slide 3: Questcor: A biopharmaceutical company whose product, Acthar, helps patients

    3 A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions Questcor A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions

  4. Slide 4: Questcor Overview

    4 Questcor Overview Flagship Product: • Profitable, cash flow positive, $209M* in cash, debt-free • 19 approved indications Key Markets: • Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms • Several billion dollar market opportunity Strategy: • Grow Acthar sales in each key market • Develop o

  5. Slide 5: Questcor Strategy - Pursue Acthar Markets

    Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Lupus Erythematosus Questcor Strategy - Pursue Acthar Markets 5 Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Lupus Erythematosus

  6. Slide 6: Acthar and Multiple Sclerosis (MS)

    Acthar and Multiple Sclerosis (MS) Neurodegenerative disorder Acute treatment for relapses 43% get better or much better 27% get only a little better 30% stay the same or get worse 6 *Nickerson, et al ( 2011) Neurodegenerative disorder Acute treatment for relapses Potential target for 43% get better

  7. Slide 7: MS Scripts - Record of Consistent Growth

    7 Paid Rxs MS Scripts-Record of Consistent Growth Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is th

  8. Slide 8: Monthly MS Scripts History

    8 Monthly MS Scripts History Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the chart.

  9. Slide 9: Acthar and Nephrotic Syndrome (NS)

    • Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unmet need – Few treatment options – Goal of therapy is the significant reduction of proteinuria Acthar and Nephrotic Synd

  10. Slide 10: NS Scripts - Strong Q4 Growth

    10 Paid Rxs NS Scripts-Strong Q4 Growth Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of

  11. Slide 11: Acthar and Infantile Spasms (IS)

    11 • FDA approval 10/15/10 • Devastating, refractory form of childhood epilepsy • IS not responsive to standard anti-epileptic drugs • Unsuccessful treatment may leave infant with permanent developmental disabilities • Considered a medical emergency • Ultra-rare orphan disorder • About half of IS pa

  12. Slide 12: IS Scripts - Higher numbers in H2 2011

    12 IS Scripts-Higher numbers in H2 2011 • Acthar currently used to treat 40-50% of IS patients • Targeting select institutions • Significant variability in quarterly Rxs • Q4-2011 paid Rxs above historic range

  13. Slide 13: Systemic Lupus Erythematosus (Lupus)

    13 • High unmet need; difficult to treat • Serious health risk if unsuccessfully treated • Multiple on-label indications for Acthar – Exacerbations – Maintenance therapy – Lupus nephritis • Large patient population Systemic Lupus Erythematosus (Lupus) • High unmet need; difficult to treat • Serious

  14. Slide 14: Financials

    14 Financials Profitable Debt Free Cash Flow Positive Profitable Debt Free Cash Flow Positive

  15. Slide 15: Q3-2011 Financial Results

    15 Q3 – 2011 Q3 – 2010 Q3-2011 Financial Results • Third quarter vials shipped: 2,910 • Third quarter cash flow from operations: $32.6M • Channel inventory estimated to be within historic range • Medicaid reserves continue to appear adequate • No shares repurchased Record Net Sales (up 91%) and Soli

  16. Slide 16: Questcor is Cash Flow Positive, Debt-free Balance Sheet

    16 01/04/12 Questcor is Cash Flow Positive Debt-free balance sheet *After return of $78 million of cash to shareholders through share repurchases. 16 Cash / ST Investments $209M* Accounts Receivable $28M Debt-free balance sheet *After return of $78 million of cash to shareholders through share repur

  17. Slide 17: Share Repurchases: 15 Million Shares

    17 • 2.2 Million Preferred share buyback • 13.2 Common share buyback • $78 million returned to shareholders in stock buybacks • 63.6 million shares currently outstanding • 4.3 million shares remain on buyback authorization Share Repurchases: 15 Million Shares Repurchased shares significantly improve

  18. Slide 18: Preliminary Q4-2011 Operating Metrics

    18 • Paid Rxs (Approximate) – MS—935-950 • October 295-300 • November 320-325 • December 320-325 – NS—140-150 – IS—120-125 • 3,360 Vials Shipped • Operating expenses expected to be up 20-30% from Q3-2011 Preliminary Q4-2011 Operating Metrics • Paid Rxs (Approximate) – MS—935-950 • October 295-300 •

  19. Slide 19: How Does Acthar Work?

    19 How Does Acthar Work? • Acthar treats autoimmune conditions across a variety of organ systems (CNS, kidney, etc.) • Acthar appears to modulate the immune system and associated inflammatory response through binding to melanocortin receptors • The primary melanocortin peptide (ACTH) in Acthar binds

  20. Slide 20: Competitive Pathways

    20 Generic Pathway Requires reverse engineering -- a difficult barrier Must prove pharmaceutical & biological equivalence Immune system impact unknown New Chemical Entity or Biosimilar Pathway Trial(s) required Limited exclusivity Results in duopoly SUBSTITUTABILITY SINGLE INDICATION COMPETITION Com

  21. Slide 21: Acthar Market Opportunity

    21 Acthar Market Opportunity Market Rx Value Market Size Total $2B+ MS $40-50K $1B+ NS $150-250K $1B+ IS $100-125K $100M Lupus Unknown Unknown Other Various Unknown

  22. Slide 22: Annualized Net Sales Run Rate by Market

    22 Market Approximate Annualized Net Sales Run Rate* Approximate Annualized Level of Business** NS Business Already Significant MS $145-160M $145-160M NS $60-70M $100-110M IS $40-50M $40-50M Note: Figures do not based on actual net sales ranges for the quarter or year ended December 31, 2011 * Figur

  23. Slide 23: Strategic Plan - Focus on the Embedded Pipeline in Acthar

    23 • Expand NS promotion effort • Expand MS promotion effort • Maintain IS promotion effort • Develop pilot rheumatology promotion activity • Develop other markets for Acthar Acthar is its own pipeline with many other on-label indications and many possible other therapeutic uses Further define and d

  24. Slide 24: Sales Force Expansion - Preliminary Outlook for 2012

    24 Sales Force Expansion- Preliminary Outlook for 2012 Q1-12 Q2 Q3 Q4 Q1-13 Possible Rheumatology Possible Rheumatology Sales Pilot Sales Pilot Neuro Hiring & Neuro Hiring & Training Training Neuro Neuro Sizing & Sizing & Alignment Alignment Neph Hiring & Neph Hiring & Training Training Neph Sizing

  25. Slide 25: Investment Highlights

    25 Investment Highlights Acthar has sustainable competitive Acthar has sustainable competitive advantages-without FDA approval risk advantages-without FDA approval risk Acthar is approved for 19 indications-many Acthar is approved for 19 indications-many in large markets with sizable unmet need in l

  26. Slide 26: January 2012 JP Morgan Healthcare Conference

    NASDAQ: QCOR January 2012 JP Morgan Healthcare Conference NASDAQ: QCOR

  27. Slide 27: ACTH is a Melanocortin Peptide Derived from POMC in the Pituitary

    27 ACTH is a Melanocortin Peptide Derived from Pro-opiomelanocortin (POMC) in the Pituitary

  28. Slide 28: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes

    28 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC1R Podocytes Renal Mesangial Cells Endothelial Cells (Glomerular, Tubular, Vascular) Tubular Epithelial Cells Macrophages Melanocyt

  29. Slide 29: Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes (cont.)

    29 MCR Prevalent Tissue/Cells with Receptor Adapted from Gong 2011, Catania 2004, Schioth 1997 Affinity of Melanocortin Peptides and Distribution of Receptor Subtypes MC3R CNS Macrophages MC4R Podocytes Renal Mesangial Cells (?) Endothelial Cells (Glomerular, Tubular) Tubular Epithelial Cells CNS MC

  30. Slide 30: MOA of Acthar in NS

    30 MOA of Acthar in NS Adapted From Gong 2011 Acthar, Melanocortin Peptides Acthar, Melanocortin Peptides

Questcor Pharmaceuticals — JP Morgan Healthcare Conference 2012 on 6ix